SCHEMBL7998701

SCHEMBL7998701

O=C(c1ccc(C(F)(F)F)cc1)C1CC1(F)F

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ BACE1 P56817 1/20 0.49
▸ GSK3B P49841 2/20 0.49
▸ PTPN1 P18031 1/20 0.49
▸ SRD5A2 P31213 1/20 0.46
▸ MAOA P21397 2/20 0.44
▸ MAOB P27338 2/20 0.44
▸ HSD11B1 P28845 1/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ MGLL Q99685 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474671 0.79 MAPT (0.43) CES2PTPN1SRD5A2HPGDMGLL
SCHEMBL31489675 0.79 SLC6A3 (0.47) CES2CES1PTPN1HSD11B1KMT2A
SCHEMBL1350004 0.78 LMNA (0.46) CES2CES1GSK3BMAOAMAOB
SCHEMBL4023293 0.76 HSD11B1 (0.63) CES2CES1BACE1GSK3BPTPN1
SCHEMBL1855141 0.73 HSD11B1 (0.60) CES2CES1SRD5A2HSD11B1MEN1
SCHEMBL19650840 0.73 HSD11B1 (0.60) CES2CES1SRD5A2HSD11B1MEN1
SCHEMBL26081057 0.71 HSD11B1 (0.58) CES2CES1SRD5A2HSD11B1MEN1
SCHEMBL23172558 0.70 CES2 (0.67) CES2CES1BACE1GSK3BPTPN1
SCHEMBL1078685 0.70 CES1 (0.67) CES2CES1GSK3BPTPN1SRD5A2
SCHEMBL648641 0.69 SRD5A2 (0.83) CES2CES1GSK3BPTPN1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063234-B2 Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-22 — — US disclosed
US-8063234-B2 Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-22 — — US disclosed
US-20110201564-A1 SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-18 — — US disclosed
US-20110201564-A1 SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-18 — — US disclosed
US-20100105744-A1 SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-29 — — US disclosed
US-20100105744-A1 SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-29 — — US disclosed
WO-2009156072-A1 SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105744-A1 SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF STS, HTR7, PCSK7 CES2 1246/4885CES1 568/4885BACE1 1674/4885
US-20110201564-A1 SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF HTR7, STS, INMT CES2 2150/4885CES1 1155/4885BACE1 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback